2019-06-17 |
114 |
Amended Complaint |
expiration of U.S. Patent Nos.
7,449,012 B2 (the “‘012 patent”) and 7,794,432 B2 (the “‘432 patent”), which expire…Numbers 7,449,012, 7,794,432, 8,048,035, and 8,870,827 (the “EpiPen Patents”). These four
patents have a …additional patents for features that were subsequently integrated into the EpiPen: U.S. Patent
Numbers…The issuance of the EpiPen Patents, and Mylan’s designation of these patents as
covering the EpiPen, …submitted information concerning the ’012 patent and ’432 patent for listing in the FDA’s
[Orange Book |
External link to document |
2019-07-31 |
123 |
Third Amended Complaint |
expiration of U.S. Patent Nos.
7,449,012 B2 (the “‘012 patent”) and 7,794,432 B2 (the “‘432 patent”), which expire…Numbers 7,449,012, 7,794,432, 8,048,035, and 8,870,827 (the “EpiPen Patents”). These four
patents have a …additional patents for features that were subsequently integrated into the EpiPen: U.S. Patent
Numbers…The issuance of the EpiPen Patents, and Mylan’s designation of these patents as
covering the EpiPen, …submitted information concerning the ’012 patent and ’432 patent for listing in the FDA’s
[Orange Book |
External link to document |
2017-03-20 |
39 |
Amended Complaint |
expiration of U.S. Patent Nos.
7,449,012 B2 (the “‘012 patent”) and 7,794,432 B2 (the “‘432 patent”), which expire…Numbers 7,449,012, 7,794,432, 8,048,035, and 8,870,827 (the “EpiPen Patents”). These four
patents have a …settling
its patent infringement suit against Teva Pharmaceuticals (“Teva”) relating to the patents
covering…additional patents for features that were subsequently integrated into the EpiPen: U.S. Patent
Numbers…The issuance of the EpiPen Patents, and Mylan’s designation of these patents as
covering the EpiPen, |
External link to document |